Clinical Trials
Pharma Trendsetters: Xceleron
Xceleron takes a novel approach at drug development: fail early, fail often. The thought is that since most drugs do fail during the drug development process, streamlining discovery means finding the drugs that will fail earlier, before the money is spent. It could lead to significant changes to the process in the future.
Pharmaceutical Profile: Sequenom
I was reading my monthly copy of Pharmaceutical Executive magazine when I came across Joanna Breitstein’s excellent article profiling the latest trend in the pharmaceutical arena: big deals that are safe bets. In her article, “Place your Bets,” Breitstein characterizes Roche’s bid to acquire Genentech as a reflection of the cautious approach to deal-making that [...]
Bridion and the Tale of Two Agencies
Once upon a time, there was a promising new drug named Bridion. It was touted by its manufacturer as the first major pharmaceutical advance in the field of anesthesia in two decades. The drug was submitted to two powerful health authorities for marketing approval. Authorization looked like a foregone conclusion as advisory committees for both [...]
The New War on Drugs: Vaccinations?
Ask yourself, when your child grows up, do you want him to be a cocaine addict? What if there was something you could do to prevent it? What if it was as easy as protecting your child against tetanus or the mumps? We may not be far away from the first vaccine to fight against [...]
Pharmaceutical start-ups: Phytomedics
I read today about a really interesting pharmaceutical company that, though it’s considered a start-up, has spent the last 12 years researching and developing new drugs and methodologies that will allow for more rapid and safer development of drug products: Phytomedics. Their focus is on botanical drugs, which, in theory, could provide many of [...]
Loading ...